ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Renal"

  • Abstract Number: LB17 • ACR Convergence 2025

    Circulating biomarkers for organ involvement in systemic lupus erythematosus: a series of systematic reviews and meta-analyses

    Sitian Zang1, Ranran Yao1, Yan Wang1, Danxue Zhu1, Jing He1 and Zhanguo Li2, 1Peking University People's Hospital, Beijing, China (People's Republic), 2Peking Univeristy People's Hospital, Beijing, China (People's Republic)

    Background/Purpose: Systemic lupus erythematosus (SLE) features heterogeneous clinical manifestations. The identification of biomarkers that facilitate initial disease recognition is a cornerstone of optimized clinical management.…
  • Abstract Number: 2014 • ACR Convergence 2025

    Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR  < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data

    Yu Xue1, Tianshu Chu2, Jiankang Hu3, Wei Gou4, Ning Zhang5, Juan Li6, Jing Yu7, Rongping Li8, Rongbin Li9, Long Qian10, Xinwang Duan11, Lihua Duan12 and Hejian Zou1, 1Department of Rheumatology,Huashan Hospital, Fudan University, Shanghai, China, shanghai, China (People's Republic), 2Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, zhengzhou, China (People's Republic), 3Department of Rheumatology, Pingxiang People's Hospital, Pingxiang,China,, Pingxiang, China (People's Republic), 4Department of Rheumatology, Hebei Petro ChinaCentral Hospital, Langfang, China, Langfang, China (People's Republic), 5Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shengjing, China (People's Republic), 6The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), 7Department of Rheumatology, The FirstAffiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), 8Department of Rheumatology, The First Affiliated Hospital of GannanMedical University, Ganzhou, China, Ganzhou, China (People's Republic), 9Department ofRheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), 10Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), 11The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), 12Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)

    Background/Purpose: Approximately 70% of adults with gout have CKD (Chronic Kidney Disease) ≥stage 3 (i.e estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2), significantly restricts treatment…
  • Abstract Number: 0650 • ACR Convergence 2025

    Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results

    Brad Rovin1, Jay Garg2, Richard Furie3, Rachel Jones4, Amit Saxena5, Pasquale Esposito6, Elsa Martins7, Claire Petry7, Nicolas Frey7, Bongin Yoo2, Imran Hassan8, Thomas Schindler7, Theodore Omachi9, William Pendergraft2, Mittermayer Santiago10, Gustavo Aroca Martínez11 and Ana Malvar12, 1The Ohio State University, Columbus, OH, 2Genentech, Inc., South San Francisco, CA, 3Division of Rheumatology, Northwell Health, Great Neck, NY, 4Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, 5Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, 6Clinica Nefrologica, Dialisi, Trapianto, Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genova, Italy, 7F. Hoffmann-La Roche Ltd, Basel, Switzerland, 8Hoffmann-La Roche Ltd, Mississauga, ON, Canada, 9Genentech, Inc., South San Francisco, 10Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Bahia, Brazil, 11Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, 12Organización Médica de Investigación, Buenos Aires, Argentina

    Background/Purpose: The Phase III REGENCY study (NCT04221477) demonstrated superiority of obinutuzumab (OBI) over placebo (PBO) in achieving complete renal response (CRR) at Week 76 when…
  • Abstract Number: 1991 • ACR Convergence 2025

    Co-Use of Mycophenolate Mofetil with Pegloticase Yielded Similar Clinical Outcomes as the Co-Use of Methotrexate

    Tingting Zhang1, Kenneth Saag2, Yasir Qazi3, Bradley Marder4 and Brian Lamoreaux5, 1Amgen, Inc., Thousand Oaks, 2The University of Alabama at Birmingham, Birmingham, AL, 3Keck School of Medicine Renal Transplant Program, University of Southern California, Los Angeles, CA, 4AMGEN, Inc, Denver, CO, 5Amgen, Inc., Deerfield, IL

    Background/Purpose: Pegloticase significantly reduces serum uric acid (sUA) values in patients with refractory gout. Co-use of methotrexate (MTX) improves efficacy and safety of pegloticase by…
  • Abstract Number: 0638 • ACR Convergence 2025

    Prevalence of lupus nephritis, end stage kidney disease, avascular necrosis, and mortality in systemic lupus erythematosus in the recent era

    Takehiro Nakai1, Sho Fukui2, Yukihiko Ikeda3, Masei Suda4, Hiromichi Tamaki1, mitsumasa kishimoto5 and Masato Okada6, 1Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, 2Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, 3St Luke's international hospital in Japan, Tokyo, Japan, 4Suwa Central Hospital, Nagano, Japan, 5Kyorin University School of Medicine, Tokyo, Japan, 6St. Luke's International Hospital, Tokyo, Japan

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with an increased risk of chronic kidney disease (CKD), avascular necrosis (AVN), and mortality. Despite…
  • Abstract Number: 1841 • ACR Convergence 2025

    Differential metabolomic signatures along lupus nephritis spectrum

    Mariana Jiménez Tirado1, karina santana2, Jiram Torres Ruiz3, Jennifer Tiaré Balderas Miranda4, Diana Gómez-Martín5, José Carlos Páez Franco6, Nancy R Mejía Domínguez7, Hilda Sánchez Vidal6 and Imelda Cecilia Zarzoza Mendoza8, 1Instituto Nacional de Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, 2INCMNSZ, Ciudad de México, Federal District, Mexico, 3INCMNSZ, Mexico, Federal District, Mexico, 4Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, 5INCMNSZ, Mexico city, Federal District, Mexico, 6Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Distrito Federal, Mexico, 7Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 8Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Lupus nephritis (LN) is a common feature in systemic lupus erythematosus (SLE) affecting up to 50% of the individuals with this disease. The gold…
  • Abstract Number: 0615 • ACR Convergence 2025

    Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant

    Jacob Klein1, Judith Lin1 and Marilly Palettas2, 1Ohio State University Wexner Medical Center, Columbus, OH, 2Center for Biostatistics Ohio State University, Columbus, OH

    Background/Purpose: It has been observed that systemic lupus erythematosus (SLE) activity often goes into remission in patients with end-stage kidney disease (ESKD) on dialysis or…
  • Abstract Number: 1835 • ACR Convergence 2025

    Serum Zonulin As A Biomarker Of Renal Involvement In Systemic Lupus Erythematosus: Shedding Light On The Gut-Kidney Axis

    Alessandra Milone1, Giulio Forte2, Alessia Salzillo2, Barbara De Marino2, Rosa Giacca2, Francesco Ciccia3 and Daniele Mauro4, 1University of Campania L. Vanvitelli, Naples, 2University of Campania L. Vanvitelli, Naples, Italy, 3Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, 4University of Campania, Italy, Naples, Italy

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease in which lupus nephritis (LN) remains a major cause of morbidity and mortality. Zonulin, a…
  • Abstract Number: 0856 • ACR Convergence 2025

    Integrated Single-Cell and Spatial Transcriptomics Reveal Vascular and Immune Pathogenesis in APS Nephropathy

    Shuyi Yu1, Haoyu Pan1, Jinyi Qian1, Xiaohan Wei2, Yuying Fan1, Zhixia Yang1, Shiyan Gu1, Jianzhou Wu1, Cenyi Wang1, Tiancheng Zhou1 and Hui Shi3, 1Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), 2Shanghai JiaoTong University, Shanghai, China (People's Republic), 3Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)

    Background/Purpose: To elucidate the molecular and cellular mechanisms underlying antiphospholipid antibody (aPL) nephropathy using integrated single-cell and spatial transcriptomic (SP) profiling of kidney tissues.Methods: Renal…
  • Abstract Number: 1768 • ACR Convergence 2025

    TREM-1 and TREM-2 Define Inflammatory and Protective Axes in ANCA-Associated Glomerulonephritis

    Lea Dionet1, Alexandre Lanau2, Paul Breillat3, Quentin Delcros4, Federica Pallotti5, Margot Poux6, Pierre Isnard1, Arthur Lavigne4, Xavier Puéchal7, alexandre karras8, Jean-Paul Duong9, Olivia Lenoir10, Pierre-Louis Tharaux11 and Benjamin Terrier12, 1INSERM, Paris, France, 2Institut Curie, Paris, France, 3INSERM, PARIS 17, Ile-de-France, France, 4AP-HP, Paris, France, 5Internal Medicine and Clinical Immunology, Rennes, France, 6Université de Paris, PARIS 04EME, France, 7Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( 75014 ), Ile-de-France, France, 8HEGP - assistance publique hopitaux de paris, paris, France, 9INSERM, Paris, 10Paris Cardiovascular Research Center, Université Paris Cité, INSERM U970, Paris, France, PARIS, Ile-de-France, France, 11Paris Cardiovascular Research Center, Université Paris Cité, INSERM U970, Paris, France, PARIS, France, 12Cochin Hospital, Paris, France

    Background/Purpose: ANCA-associated vasculitis (AAV) is a small-vessel vasculitis that can lead to life-threatening renal injury. Neutrophils, monocytes and macrophages play a pivotal role not only…
  • Abstract Number: 0838 • ACR Convergence 2025

    Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients With Lupus Nephritis: A Retrospective Cohort Study in the United States

    Lisa Lindsay1, Shu Wang2, Huong Trinh1, Yunru Huang1, William Pendergraft1 and Brad Rovin3, 1Genentech, Inc., South San Francisco, CA, 2Genesis Research LLC, Hoboken, NJ, 3The Ohio State University, Columbus, OH

    Background/Purpose: Complete renal response (CRR) and flare prevention, as early markers of long-term kidney survival, are important outcomes in lupus nephritis (LN) clinical trials.Methods: This…
  • Abstract Number: 1722 • ACR Convergence 2025

    Defining Safe Hydroxychloroquine Blood Levels: Time to Switch to Precision Monitoring for Optimized Lupus Care

    Shivani Garg1, Benoit Blanchet2, Yann Nguyen3, Fauzia Hollnagel4, Ada Clarke5, Michelle Petri6, Murray Urowitz7, John Hanly8, Caroline Gordon9, Sang-Cheol Bae10, Juanita Romero-Diaz11, Jorge Sanchez-Guerrero12, Ann Clarke13, Sasha Bernatsky14, Daniel Wallace15, David A. Isenberg16, Anisur Rahman16, Joan Merrill17, Paul Fortin18, Dafna D. Gladman19, Ian Bruce20, Ellen Ginzler21, Mary Anne Dooley22, Rosalind Ramsey-Goldman23, Susan Manzi24, Andreas Jönsen25, Graciela Alarcón26, Ronald van Vollenhoven27, Cynthia Aranow28, Murat Inanc29, Meghan mackay30, Guillermo Ruiz-Irastorza31, S. Sam Lim32, Murat Inac33, Kenneth Kalunian34, Søren Jacobsen35, Christine Peschken11, Diane Kamen36, Anca Askanase37, Jill Buyon38, Julie Chezel5, Alicja Puszkiel39 and Nathalie Costedoat-Chalumeau40, 1University of Madison, School of Medicine and Public Health, Madison, WI, 2National Referral Centre for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Paris, France, 3Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, 4University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, 5Cochin Hospital, Paris, France, 6Johns Hopkins University School of Medicine, Timonium, MD, 7University of Toronto, Toronto, ON, Canada, 8Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, 9Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, 10Hanyang University Medical Center, Seoul, South Korea, 11University of Manitoba, Winnipeg, MB, Canada, 12Mount Sinai Hospital and University Health Network, Toronto, Canada, 13Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 14Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 15Cedars Sinai Medical Center, Studio City, CA, 16University College London, London, United Kingdom, 17Oklahoma Medical Research Foundation, Oklahoma, 18Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 19Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, 20Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom, 21SUNY Downstate Health Sciences University, New York, NY, 22UNC physician network, Chapel Hill, NC, 23Northwestern University Feinberg School of Medicine, Chicago, IL, 24Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, 25Department of Clinical Sciences, Lund University, Lund, Sweden, 26The University of Alabama at Birmingham, Oakland, CA, 27Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, 28Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, 29Istanbul University, Istanbul, Turkey, 30Feinstein Institutes for Medical Research, Manhasset, NY, 31Biobizkaia Health Research Institute, Barakaldo, Spain, 32Emory University School of Medicine, Atlanta, GA, 33Istanbul University, Istanbul, 34UC San Diego, La Jolla, CA, 35Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 36Medical University of South Carolina, Johns Island, SC, 37Columbia University Medical Center, New York, NY, 38NYU Grossman School of Medicine, New York, NY, 39Cochin Hospital, Paris, 40Inserm DR Paris 5, Paris, France

    Background/Purpose: Current guidelines recommend using hydroxychloroquine (HCQ) dose ≤5.0 mg/kg for managing SLE. However, 6-fold higher SLE flares, including those requiring hospitalizations, are noted with…
  • Abstract Number: 1707 • ACR Convergence 2025

    Racial and Ethnic Disparities in Kidney Transplant Outcomes Among Patients With Systemic Lupus Erythematosus (SLE): A 20-Year Analysis Spanning Before and After the 2014 Kidney Allocation System Revision

    Soziema Salia1, Boniface Mensah2, Ufuoma Mamoh1, Gilava Hedayati1, Terrylyna Baffoe-Bonnie3, Joan Morny4 and Christhopher Haas3, 1MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, MD, 2MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, CA, 3MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, 4Piedmont Athens Regional Internal Medicine Residency Program, Athens, GA

    Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of end-stage kidney disease (ESKD) in young women, particularly among racial and ethnic minorities. Kidney transplantation…
  • Abstract Number: 1546 • ACR Convergence 2025

    Tacrolimus Versus Voclosporin for Active Lupus Nephritis: A Comparative Meta-analysis of Renal Response

    Urvi Zala1 and Rushi Patel2, 1Loyola MacNeal Hospital, Berwyn, IL, Oak Park, IL, 2Baptist Hospitals of Southeast Texas, Beumont, TX

    Background/Purpose: Lupus nephritis (LN) is seen in approximately 40–60 % of patients with systemic lupus erythematosus (SLE) and contributes significantly to morbidity and mortality in…
  • Abstract Number: PP08 • ACR Convergence 2025

    Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient

    Matt Makara, Casey Hogan

    Background/Purpose: Typically, the diagnosis of any autoimmune condition can be challenging and take years. In my case, my diagnosis of Sjögren's disesase (SjD) was established…
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology